Roswell Park Comprehensive Cancer Center will present new research at the 2025 San Antonio Breast Cancer Symposium (SABCS), showcasing advances in precision medicine for breast cancer treatment. More than a dozen research teams from Roswell Park will share findings that span clinical trials, health disparities, artificial intelligence, and novel treatment strategies, focusing on improving outcomes and quality of life for breast cancer patients.
Sheheryar Kabraji, Chief of Breast Medicine at Roswell Park, emphasized the center’s dedication to addressing key challenges in breast cancer through the work of faculty and trainees. Kazuaki Takabe, Chief of Breast Surgery and The Alfiero Foundation Endowed Chair in Breast Oncology, highlighted the integration of molecular signatures and immune microenvironment studies to develop personalized surgical and medical approaches.
Key presentations on Wednesday, December 10, include comparative analyses of chemotherapy and HER2-targeted therapy in elderly patients, gaps in sexual health counseling from a global oncology trainee perspective, and real-world studies on the impact of diabetes and glucagon-like peptide-1 receptor agonists on breast cancer outcomes. Additional research will focus on developing patient-derived xenografts following CDK4/6 inhibitor therapy, the role of TP53 mutations in treatment duration, and the epithelial-mesenchymal transition signature in tumors.
Thursday, December 11, features evaluations of large language models for clinical decision support in breast cancer care, germline mutations unrelated to breast cancer, tumor progression markers in triple-negative breast cancer, and analysis of Bruton’s tyrosine kinase expression in breast tumors. Other topics include spatial biomarker associations for CAR-T cell therapy, global disparities in breast cancer clinical trials, and the impact of insurance status on young breast cancer patients’ outcomes.
On Friday, December 12, research presentations will cover real-world outcomes of Capivasertib use in metastatic breast cancer and a phase II trial combining tamoxifen with pegylated liposomal doxorubicin in patients with metastatic triple-negative breast cancer.
The San Antonio Breast Cancer Symposium, hosted by the Mays Cancer Center at the University of Texas Health Science Center at San Antonio in partnership with the American Association for Cancer Research, is the world’s largest breast cancer research conference. This year’s meeting, from December 10 to 13, is expected to attract over 11,000 clinicians, researchers, and patient advocates from more than 102 countries.
Founded in 1898, Roswell Park Comprehensive Cancer Center is a leader in cancer research and treatment innovations, recognized as “Exceptional” by the National Cancer Institute. The center serves patients across New York State, combining compassionate care with cutting-edge science. For more information, visit www.roswellpark.org or contact 1-800-ROSWELL.
Leave a Reply